Imagine a world where ADHD treatment isn’t a guessing game. That’s the bold vision behind HarmonEyes’ recent acquisition of iFocus Health, a move that promises to revolutionize how we approach ADHD care. But here’s where it gets controversial: can eye-tracking technology truly replace traditional, subjective methods of assessing treatment efficacy? Let’s dive in.
HarmonEyes, a trailblazer in AI-driven eye-tracking software, has officially acquired iFocus Health, a company known for its clinically validated ADHD treatment monitoring solution. This acquisition isn’t just a business deal—it’s a game-changer for the millions of individuals and families navigating the complexities of ADHD. By integrating iFocus’s eye-tracking technology into its growing human performance platform, HarmonEyes is addressing a critical gap in ADHD care: the lack of reliable, real-time biomarkers to measure treatment effectiveness.
And this is the part most people miss: Traditional ADHD treatment adjustments rely heavily on self-reports, behavioral checklists, and provider observations—methods that often leave patients and families in the dark. iFocus Health flipped the script by tracking subtle changes in eye movement during everyday activities like reading. This approach provides clinicians with objective, actionable data, transforming ADHD treatment from a trial-and-error process into a journey of measurable progress. As Adi Diner, CEO and co-founder of iFocus Health, aptly puts it, ‘ADHD isn’t just about distraction; it’s about underperformance in a world that demands focus.’ With HarmonEyes’ backing, this technology is poised to scale, offering hope to millions more.
Rebranded as HarmonEyes Focus, the acquired technology now plays a pivotal role in HarmonEyes’ broader mission: to use eye movement as a window into human performance. HarmonEyes’ AI models already deliver real-time insights into cognitive, emotional, and physical states. With iFocus’s capabilities, they’re adding a critical layer—measuring and improving individual responses to ADHD treatment. Whether in healthcare, education, or daily life, the goal remains clear: to help people perform at their best by understanding the brain in motion.
Here’s a startling fact: According to the CDC, 6 million children and 16 million adults in the U.S. have been diagnosed with ADHD. Yet, medication management still largely depends on self-reporting and outdated behavior checklists. HarmonEyes Focus is set to change that by offering clinicians a data-driven, real-time view of medication effectiveness. This allows for more precise adjustments in dosages, timing, and treatment types, reducing guesswork and increasing confidence. It’s an approach that aligns seamlessly with HarmonEyes’ existing work in real-time cognitive state detection across industries.
But here’s the controversial question: Can technology truly replace human intuition in healthcare? Adam Gross, CEO and co-founder of HarmonEyes, believes so. He sees this acquisition as a step toward building the world’s first foundational model for eye-tracking to understand the human state. By combining iFocus’s objective measurement approach with HarmonEyes’ real-time AI platform, they’re unlocking new possibilities for focus, readiness, and mental performance across various life domains.
This acquisition isn’t just about ADHD. It signals a broader opportunity to bring objectivity into high-stakes human decision-making. In the future, this platform could be adapted to support other neurodivergent conditions, optimize classroom or workplace performance, or enhance focus and recovery in clinical settings. The potential is vast, but so are the questions. Is this the future of personalized care, or are we risking over-reliance on technology? We’d love to hear your thoughts in the comments.
For those eager to learn more about HarmonEyes and its innovative solutions, visit www.harmoneyes.com. With over 60 years of eye-tracking expertise and the largest validated eye-tracking database (14 million unique records), HarmonEyes is leading the charge in understanding and enhancing human performance. Will you join the conversation?
